Who are Albuterol MDPI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Albuterol eMDPI DS, Varied albuterol dose response, terbutaline sulfate (Bricasol), racemic albuterol MDI, albuterol inhalation powder, Ventolin® MDI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albuterol-mdpi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Albuterol MDPI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Albuterol MDPI (Albuterol MDPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic agonist (short-acting bronchodilator). Area: Respiratory.

phase 3 Beta-2 adrenergic agonist (short-acting bronchodilator) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Albuterol MDPI (Albuterol MDPI) — Teva Branded Pharmaceutical Products R&D, Inc.. Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Albuterol MDPI TARGET	Albuterol MDPI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
Albuterol eMDPI DS	Albuterol eMDPI DS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
Varied albuterol dose response	Varied albuterol dose response	Oregon Health and Science University	marketed	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
terbutaline sulfate (Bricasol)	terbutaline sulfate (Bricasol)	AstraZeneca	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor (ADRB2)
racemic albuterol MDI	racemic albuterol MDI	Sumitomo Pharma America, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
albuterol inhalation powder	albuterol inhalation powder	Amphastar Pharmaceuticals, Inc.	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor
Ventolin® MDI	Ventolin® MDI	Taiwan Otsuka Pharm. Co., Ltd	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-2 adrenergic agonist (short-acting bronchodilator) class)

Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
Amphastar Pharmaceuticals, Inc. · 1 drug in this class
AstraZeneca · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sumitomo Pharma America, Inc. · 1 drug in this class
Taiwan Otsuka Pharm. Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Albuterol MDPI — Competitive Intelligence Brief. https://druglandscape.com/ci/albuterol-mdpi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing